Analysed MINK THERAPEUTICS INC (INKT:NASDAQ) News Sources
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
12-05-2026
yahoo.com
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
14-05-2026
yahoo.com
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
15-05-2026
yahoo.com
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...
15-05-2026
yahoo.com
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
20-05-2026
yahoo.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
28-05-2026
yahoo.com
What is the current price of MINK THERAPEUTICS INC (INKT:NASDAQ)?
The current price of MINK THERAPEUTICS INC (INKT:NASDAQ) is $12.03.
MINK THERAPEUTICS INC (INKT:NASDAQ) absolute price change since previous trading day?
The absolute price change of MINK THERAPEUTICS INC (INKT:NASDAQ) since the previous trading day is $-0.305.
MINK THERAPEUTICS INC (INKT:NASDAQ) percentage price change since previous trading day?
The percentage price change of MINK THERAPEUTICS INC (INKT:NASDAQ) since the previous trading day is -2.4726%.
What is the most recent average sentiment score for MINK THERAPEUTICS INC (INKT:NASDAQ)?
The most recent average sentiment score for MINK THERAPEUTICS INC (INKT:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for MINK THERAPEUTICS INC (INKT:NASDAQ)?
The most recent sentiment for MINK THERAPEUTICS INC (INKT:NASDAQ) is .
SEC-8K** Filing Available For MINK THERAPEUTICS INC (INKT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.